GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actelion Ltd (OTCPK:ALIOF) » Definitions » Gross Profit

Actelion (Actelion) Gross Profit : $2,233 Mil (TTM As of Mar. 2017)


View and export this data going back to . Start your Free Trial

What is Actelion Gross Profit?

Actelion's gross profit for the three months ended in Mar. 2017 was $580 Mil. Actelion's gross profit for the trailing twelve months (TTM) ended in Mar. 2017 was $2,233 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Actelion's gross profit for the three months ended in Mar. 2017 was $580 Mil. Actelion's Revenue for the three months ended in Mar. 2017 was $645 Mil. Therefore, Actelion's Gross Margin % for the quarter that ended in Mar. 2017 was 89.88%.

Actelion had a gross margin of 89.88% for the quarter that ended in Mar. 2017 => Durable competitive advantage


Actelion Gross Profit Historical Data

The historical data trend for Actelion's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actelion Gross Profit Chart

Actelion Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,662.93 1,764.58 1,786.54 1,878.47 2,131.06

Actelion Quarterly Data
Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 551.76 554.58 573.28 525.30 579.98

Competitive Comparison of Actelion's Gross Profit

For the Biotechnology subindustry, Actelion's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Actelion's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actelion's Gross Profit distribution charts can be found below:

* The bar in red indicates where Actelion's Gross Profit falls into.



Actelion Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Actelion's Gross Profit for the fiscal year that ended in Dec. 2016 is calculated as

Gross Profit (A: Dec. 2016 )=Revenue - Cost of Goods Sold
=2371.923 - 240.865
=2,131

Actelion's Gross Profit for the quarter that ended in Mar. 2017 is calculated as

Gross Profit (Q: Mar. 2017 )=Revenue - Cost of Goods Sold
=645.285 - 65.309
=580

Gross Profit for the trailing twelve months (TTM) ended in Mar. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $2,233 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Actelion's Gross Margin % for the quarter that ended in Mar. 2017 is calculated as

Gross Margin % (Q: Mar. 2017 )=Gross Profit (Q: Mar. 2017 ) / Revenue (Q: Mar. 2017 )
=(Revenue - Cost of Goods Sold) / Revenue
=580 / 645.285
=89.88 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Actelion  (OTCPK:ALIOF) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Actelion had a gross margin of 89.88% for the quarter that ended in Mar. 2017 => Durable competitive advantage


Actelion Gross Profit Related Terms

Thank you for viewing the detailed overview of Actelion's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Actelion (Actelion) Business Description

Traded in Other Exchanges
N/A
Address
Actelion is a Swiss biopharmaceutical firm with several products on the market, largely focused on pulmonary arterial hypertension: Tracleer, Opsumit, Uptravi, Ventavis, and Veletri treat various stages of the disease via different methods of administration. Zavesca is a second-line option for Gaucher disease, and Valchlor treats a rare form of blood cancer. Actelion has created a global commercial infrastructure for its approved orphan drugs and has supplemented its internal pipeline through in-licensing and acquisitions.

Actelion (Actelion) Headlines

From GuruFocus

Jean Hynes Reduces Stake in Actelion

By Kyle Ferguson Kyle Ferguson 08-03-2016

Eaton Vance Worldwide Health Sciences Fund 4th Quarter Commentary

By Holly LaFon Holly LaFon 01-24-2017

Actelion Still On Growth Track

By reports.droy reports.droy 02-18-2015

Eaton Vance Worldwide Health Sciences Fund 4th Quarter Commentary

By Holly LaFon Holly LaFon 02-14-2017